The MADIT S-ICD trial is designed to evaluate if subjects with a prior myocardial infarction, diabetes mellitus and a relatively preserved ejection fraction of 36-50% will have a survival benefit from receiving a subcutaneous implantable cardioverter defibrillator (S-ICD) when compared to those receiving conventional medical therapy.
MADIT S-ICD
Multicenter Automatic Defibrillator Implantation Trial with Subcutaneous Implantable Cardioverter Defibrillator
Myocardial heart disease
All genders
65+
Recruiting now
Overview
Principal Investigator: Christopher Madias, MD
Contact Us
Melaine Marshall, RN
Study details
Inclusion Criteria
- Prior Myocardial Infarction
- Presence of Diabetes Mellitus for greater than 3 months
- Ejection Fraction between 36-50%
Exclusion Criteria
- Under age of 65
- Ejection fraction outside range of 36-50%
- No prior myocardial infarction
Study Requirements
In this study, subjects will be randomized to receive a subcutaneous implantable cardioverter defribillator or Conventional Medical Therapy (CMT). Randomization will be stratified by enrolling site, in 2:1 (S-ICD:CMT) scheme. Length of follow up for each subject will be dependent on the date of entry into this study, since all subjects will be followed to a common study termination date.